JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , announced today that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for the treatment of patients with recurrent glioblastoma (GBM) using the Alpha DaRT technology. “This is very exciting news for... Read More

Interim results from three trials exploring the use of Alpha DaRT ® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile Systemic ORR and complete response rates meaningfully higher thus far than historical Keytruda ® monotherapy data in interim read out of a combination trial of Alpha DaRT and Keytruda in treating recurrent... Read More

JERUSALEM, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that CFO Raphi Levy will present at the following investor conferences in March 2025. Event: Investor Summit Event Format: Presentation Date: March 11, 2025 Time: 12:00PM – 12:30PM ET Location: Virtual Event:... Read More

JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced the achievement of Medical Device Single Audit Program (MDSAP) certification for the company’s manufacturing facility in Jerusalem, as part of the Company’s commitment to quality, safety, and regulatory... Read More

JERUSALEM, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , announced today an approval from the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) supplement to the IDE previously announced on Jan 27, 2025, which had approved a clinical study examining... Read More

High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of Alpha DaRT ® Ad-hoc analyses of pancreatic cancer population subgroups suggest meaningful improvement in median overall survival (OS) for patients treated with Alpha DaRT after prior therapy, compared to previously published studies of alternative monotherapies, across all analyzed... Read More

JERUSALEM, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , announced today that an abstract entitled “ Interim analysis of feasibility, safety, and tumor control in two first-in-human trials of a novel alpha-emitting radionuclide for pancreatic adenocarcinoma ,” submitted by principal... Read More

JERUSALEM, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , announced today that following its Annual General Meeting of Company shareholders in Jerusalem, Ms. Maya Netser has been appointed to the Company’s Board of Directors (“Board”). Mr. Meir Jakobsohn is completing his term on the... Read More

JERUSALEM, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 43 rd Annual Healthcare Conference on Thursday, January 16, 2025 at 9:45am PT / 12:45pm ET, in San Francisco,... Read More

JERUSALEM, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that CFO Raphi Levy will present at the Ladenburg Oncology Innovators & Investors Symposium. Event: Ladenburg Oncology Innovators & Investors Symposium Format: Presentation and 1-on-1 Meetings Date: December 12,... Read More

Alpha DaRT ® accepted into the prestigious Total Product Life Cycle Advisory Program (TAP) of the FDA, to accelerate market access to the Alpha DaRT ® for patients with recurrent glioblastoma multiforme (GBM) First patient treated in Recurrent Lung Cancer study in Israel, which will assess the safety and feasibility of delivering Alpha DaRT ® sources into the lung using an endobronchial ultrasound procedure FDA approval of... Read More

JERUSALEM, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that CFO Raphi Levy will participate in the Citi 2024 Global Healthcare Conference on December 3 rd , 2024 and the Piper Sandler 36 th Annual Healthcare Conference on December 5 th , 2024. Event: Citi 2024... Read More

JERUSALEM, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-emitters cancer therapy Alpha DaRT®, announced today that it has been accepted into the prestigious Total Product Life Cycle (TPLC) Advisory Program (“TAP”) Pilot of the U.S. Food and Drug Administration (“FDA”), to accelerate market access to the Alpha DaRT for... Read More

JERUSALEM, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , announced today that its first patient with recurrent lung cancer has been treated, in a clinical trial at Hadassah Medical Center in Jerusalem, Israel. The trial is designed to treat up to ten patients with recurrent tumors in... Read More

JERUSALEM, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) application to initiate a multi-center study for the treatment of recurrent cutaneous Squamous Cell... Read More

JERUSALEM, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that CFO Raphi Levy will present a corporate overview and update at the H.C. Wainwright 26 th Annual Global Investment Conference on September 10 th , 2024 and in the Sidoti Virtual Investor Conference on... Read More

First patient treated in May for liver metastases from colorectal cancer Publication in June in Cancers journal of long-term safety and efficacy data in multiple hard-to-treat superficial cancers, with an overall response rate of almost 100% in treated lesions, no moderate or severe long-term toxicities noted, and a 2-year local recurrence-free survival was estimated at 77% Cash, cash equivalents & deposits balance of $74.1... Read More

The pooled analysis included data from 4 international clinical trials spanning an array of hard-to-treat indications including skin, head & neck, and oral cavity. Initial response data demonstrated an overall response rate of almost 100% in treated lesions and a complete response rate of 89%. With follow-up as long as 51 months (median follow-up of 14-months), no moderate or severe long-term toxicities were noted, and... Read More

JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview and update at the Jefferies Global Healthcare Conference on June 5 th , 2024. Event: Jefferies Global Healthcare Conference Date: June 5th, 2024 Time: 1:30-1:55... Read More

Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024 Congress in Glasgow First patient with liver metastases treated in a feasibility and safety study of Alpha DaRT at the McGill University Health Center in Montreal, Canada Patient recruitment for ReSTART U.S. multi-center pivotal trial and for pancreatic cancer feasibility and safety studies in Canada and Israel... Read More

JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with liver cancer metastases has been treated in a feasibility and safety study of Alpha DaRT at the McGill University Health Center in Montreal, Canada. The trial seeks to recruit up to 10... Read More

Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone Effect seen across both Panc02 and KPC tumor models JERUSALEM, May 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,... Read More

JERUSALEM, May 01, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present at the following investor conferences in May 2024. Event: Guggenheim Securities Radiopharmaceuticals Day Format: Presentation Date: May 13, 2024 Time: 11:30AM ET Location: New York,... Read More

JERUSALEM, March 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview and update at the Jefferies Radiopharma Innovation Summit on April 11 th , 2024. Event: Jefferies Radiopharma Innovation Summit Date: April 11, 2024 Time:... Read More

Positive interim safety and feasibility data from pancreatic cancer study in Montreal, with initial signs of potential dose response findings ReSTART U.S. multi-center pivotal trial currently underway Submitted PMDA application for recurrent Head and Neck cancer in Japan Entered into long-term lease for a second facility in the U.S. in Hudson, NH Cash, deposits and restricted deposits balance of $84.9 million, with... Read More

JERUSALEM, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate at the Barclays 26 th Annual Global Healthcare Conference on March 12 th and 13 th , 2024. Event: Barclays 26 th Annual Global Healthcare Conference Format: 1-on-1 Meetings Date:... Read More

The overview presentation will review some of the Company’s recent achievements, including highly promising interim results from the Company’s pancreatic cancer safety and feasibility trial as well as robust long-term data analyzed across four clinical trials The Company will also be featured at the Biotech Showcase™ occurring in parallel, and will host institutional investor meetings at both conferences JERUSALEM, Dec. 20,... Read More

JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will present at the Sidoti Small-Cap Virtual Conference on Thursday, December 7 th , 2023. Format: Presentation and 1-on-1 meetings Date: December 7 th , 2023 Time: 9:15 AM ET Location: Virtual... Read More

Interim data read-out of the first five treated patients demonstrated successful delivery in all five cases, as well as no product-related Serious Adverse Events First five patients received conservative partial tumor coverage, and in patients with higher radium-224 levels, increased tumor responses were observed, with the last three patients presenting two stable disease responses and one partial response at last... Read More

JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and HekaBio K.K. (“HekaBio”) a Japan-based healthcare investment, development and commercialization platform which is partnered with Alpha Tau, announced today that Japan’s Pharmaceuticals and Medical Devices Agency (“PMDA”) has accepted Alpha... Read More

Treated the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel in September, alongside safety and feasibility trial in similar indication currently underway in Montreal, Canada 89% CR, two-year local recurrence-free survival of 77%, and no treatment-related grade 2 or higher late-onset toxicity reported from an analysis of four feasibility trials in 71 patients with unresectable... Read More

JERUSALEM, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor conferences in November 2023. Event: Emerging Growth Conference Format: Company presentation and 1-on-1 meetings Date: Thursday, November 2 nd , 2023 Time... Read More

JERUSALEM, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its U.S. subsidiary, Alpha Tau Medical Inc., has entered into a long-term lease agreement for a standalone building of over 14,000 rentable square feet in Hudson, New Hampshire, with the intention of erecting... Read More

JERUSALEM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Stephen M. Hahn, M.D., former commissioner of the U.S. Food and Drug Administration (“FDA”), has joined its Scientific Advisory Board. A distinguished expert in the field of radiation oncology and... Read More

JERUSALEM, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that a patient with advanced inoperable pancreatic cancer has been treated in a clinical trial at Hadassah Medical Center in Jerusalem, Israel. The trial is designed for a broad range of solid tumor patients who... Read More

Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in April 89% CR, two-year local recurrence-free survival of 77%, and no treatment-related grade 2 or higher late-onset toxicity reported from an analysis of four feasibility trials in 71 patients with unresectable skin and head and neck cancers Valuable land grant received in Jerusalem to enable a standalone... Read More

JERUSALEM, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor conferences. Event: Citi’s 2023 Annual BioPharma Conference Format: 1-on-1 meetings Date: September 6 th , 2023 Location: Boston, MA Event: Emerging... Read More

81 lesions treated across four feasibility trials of head and neck or skin cancers demonstrated 89% complete response rate. Two-year local recurrence-free survival rate of 77%. The analysis also showed no grade 3 or higher acute treatment-related toxicities, with approx. 20% of patients experiencing acute grade 2 toxicities. No grade 2 or higher late toxicities were observed 6 months after treatment. JERUSALEM, Aug. 17, 2023... Read More

JERUSALEM, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that Raphi Levy, Chief Financial Officer, will present at the Emerging Growth Conference on August 9 th , 2023. Please register here to ensure you are able to attend the conference and receive any updates that are... Read More

JERUSALEM, May 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor conferences. Event: Jefferies Healthcare Conference Format: Presentation and 1-on-1 meetings Date: Wednesday, June 7 Time: 2:30 p.m. Eastern Time Location:... Read More

Opened U.S. multicenter pivotal trial in recurrent cutaneous skin cancer, which began enrolling patients in March Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in April Results of U.S. multicenter pilot trial in skin cancer published in JAMA Network Open in May Treated the first patient with squamous cell carcinoma of the vulva in a safety and feasibility in... Read More

JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with squamous cell carcinoma of the vulva has been treated in a feasibility and safety study of Alpha DaRT at Addenbrookes Hospital of the Cambridge University Hospitals NHS Foundation Trust... Read More

The trial demonstrated a 100% Complete Response rate at 12 weeks post treatment and no device-related serious adverse events or systemic toxicity reported in the 10 patients treated in the feasibility and safety study of intratumoral Alpha DaRT for the treatment of recurrent or unresectable skin cancer. CT scan data at 24 weeks post-treatment showed no evidence of recurrent disease in any of the ten patients, and no... Read More

JERUSALEM, May 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that Raphi Levy, Chief Financial Officer, will take part in a fireside chat at the Guggenheim Radiopharmaceuticals Day in New York City on Monday, May 15 th , 2023. Event: Guggenheim Radiopharmaceuticals Day Date:... Read More

JERUSALEM, April 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with advanced inoperable pancreatic cancer has been treated in a feasibility and safety study of Alpha DaRT at the Jewish General Hospital (“JGH”) in Montreal, Canada, which is an... Read More

JERUSALEM, March 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that Raphi Levy, Chief Financial Officer, will present in-person at the Jefferies Radiopharma Innovation Summit in New York City on Monday, April 3 rd , 2023. Event: Jefferies Radiopharma Innovation Summit Date:... Read More

JERUSALEM, March 12, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today issued the following statement on Silicon Valley Bank (SVB) in response to questions from investors and analysts. We maintain no accounts or other financial relationships with SVB, and we do not currently expect its... Read More

Opened U.S. pivotal trial in recurrent cutaneous squamous cell carcinoma, which began enrolling patients in March Received Health Canada approval to initiate a liver cancer feasibility trial Pursued supply chain expansion in Israel, the U.S. and Japan, including increases in radioactive license capacities Cash & equivalents balance of $105.4 million, with runway for at least two years JERUSALEM, March 09, 2023 (GLOBE... Read More

-First two US patients with recurrent cutaneous squamous cell carcinoma have been treated at University Cancer Center in Houston, Texas -Up to 86 patients to be enrolled in the U.S., Canada, Europe and Israel to assess the efficacy and safety of intratumoral Alpha DaRT for the treatment of patients with recurrent cutaneous squamous cell carcinoma JERUSALEM, March 08, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha... Read More

JERUSALEM, March 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the Israeli Ministry of Environmental Protection has granted the Company an amended radioactive license in the main manufacturing floor of its production facility in Jerusalem, increasing the maximum... Read More

JERUSALEM, March 01, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has received authorization from Health Canada to proceed with a feasibility and safety study of Alpha DaRT in the treatment of liver metastases, subject to final approval by an institutional Research... Read More

JERUSALEM, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau," or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the Company plans to participate in Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference on March 1, 2023 taking place at Citi HQ Conference Center in New York City. Citi’s 2023 Healthcare... Read More